Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Peginterferon→

Peginterferon Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
215647-85-1
Molecular formula
Not available
Molecular weight
~40000 g/mol
Drug class
Pegylated interferon alfarecombinant cytokine immunomodulator and antiviral agent
Mechanism of action
A covalent conjugate of recombinant interferon alfa and polyethylene glycol. Binding to cell-surface interferon receptors triggers JAK-STAT signalling and transcription of interferon-stimulated genes, producing antiviral, antiproliferative and immunomodulatory effects. PEG conjugation reduces clearance and prolongs systemic exposure.
Indications / reported uses
  • The term peginterferon covers multiple subtype-specific products (for example peginterferon alfa-2a and alfa-2b) with distinct labels. Depending on the subtype and product, indications have included chronic hepatitis B or C and selected myeloproliferative neoplasms; use the exact peginterferon product label for clinical indications.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys · https://www.ema.europa.eu/en/documents/product-information/pegintron-epar-product-information_en.pdf · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/peginterferon-alfa-2a · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Pegylated interferon alfa; recombinant cytokine immunomodulator and antiviral agent

Mechanism of action

A covalent conjugate of recombinant interferon alfa and polyethylene glycol. Binding to cell-surface interferon receptors triggers JAK-STAT signalling and transcription of interferon-stimulated genes, producing antiviral, antiproliferative and immunomodulatory effects. PEG conjugation reduces clearance and prolongs systemic exposure.

General use cases

  • The term peginterferon covers multiple subtype-specific products (for example peginterferon alfa-2a and alfa-2b) with distinct labels. Depending on the subtype and product, indications have included chronic hepatitis B or C and selected myeloproliferative neoplasms; use the exact peginterferon product label for clinical indications.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Peginterferon Environmental Risk Assessment (ERA) (the Peginterferon ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.